Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use

Journal of Clinical Oncology

Volumn 28, Issue 35, 2010, Pages 5140-5146

  Farhat, Ghada N ^a   Walker, Rod ^a   Buist, Diana S M ^a   Onega, Tracy ^a   Kerlikowske, Karla ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; FEMALE; HORMONAL THERAPY; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED;

EID: 79951884699     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.5121     Document Type: Article

References (33)

1. Howe HL, Wu X, Ries LA, et al: Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107:1711-1742, 2006
2. Ravdin PM, Cronin KA, Howlader N, et al: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674, 2007
3. Buist DS, Newton KM, Miglioretti DL, et al: Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104:1042-1050, 2004 (Pubitemid 40458772)
4. Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 291:47-53, 2004 (Pubitemid 38040534)
5. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002 (Pubitemid 34761611)
6. Lambe M, Wigertz A, Holmqvist M, et al: Reductions in use of hormone replacement therapy: Effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 121:679-683, 2010
7. Clarke CA, Glaser SL: Declines in breast cancer after the WHI: Apparent impact of hormone therapy. Cancer Causes Control 18:847-852, 2007 (Pubitemid 47125116)
8. Glass AG, Lacey JV Jr, Carreon JD, et al: Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:1152-1161, 2007
9. Robbins AS, Clarke CA: Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25:3437-3439, 2007
10. Parkin DM: Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 45:1649-1653, 2009
11. Canfell K, Banks E, Moa AM, et al: Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188:641-644, 2008
12. Vankrunkelsven P, Kellen E, Lousbergh D, et al: Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 118:425-432, 2009
13. Chlebowski RT, Kuller LH, Prentice RL, et al: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573-587, 2009
14. Breen N, Cronin AK, Meissner HI, et al: Reported drop in mammography: Is this cause for concern? Cancer 109:2405-2409, 2007
15. Kerlikowske K, Miglioretti DL, Buist DS, et al: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99:1335-1339, 2007 (Pubitemid 47394172)
16. Yankaskas BC, Taplin SH, Ichikawa L, et al: Association between mammography timing and measures of screening performance in the United States. Radiology 234:363-373, 2005 (Pubitemid 40139904)
17. Lane PW, Nelder JA: Analysis of covariance and standardization as instances of prediction. Biometrics 38:613-621, 1982 (Pubitemid 13286338)
18. Graubard BI, Korn EL: Predictive margins with survey data. Biometrics 55:652-659, 1999 (Pubitemid 29302598)
19. Coombs NJ, Cronin KA, Taylor RJ, et al: The impact of changes in hormone therapy on breast cancer incidence in the US population. Cancer Causes Control 21:83-90, 2010
20. Reeves GK, Beral V, Green J, et al: Hormonal therapy for menopause and breast-cancer risk by histological type: A cohort study and meta-analysis. Lancet Oncol 7:910-918, 2006 (Pubitemid 44615945)
21. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al: Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21:4314-4321, 2003 (Pubitemid 46621806)
22. Eheman CR, Shaw KM, Ryerson AB, et al: The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. Cancer Epidemiol Biomarkers Prev 18:1763-1769, 2009
23. Menes TS, Kerlikowske K, Jaffer S, et al: Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: Findings from the Breast Cancer Surveillance Consortium. Cancer Epidemiol Biomarkers Prev 18:2822-2828, 2009
24. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 289:3243-3253, 2003 (Pubitemid 37430077)
25. Jemal A, Ward E, Thun MJ: Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9:R28, 2007
26. Bevers TB, Anderson BO, Bonaccio E, et al: NCCN clinical practice guidelines in oncology: Breast cancer screening and diagnosis. J Natl Compr Canc Netw 7:1060-1096, 2009
27. Li CI, Daling JR: Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 16:2773-2780, 2007
28. Onega T, MacKenzie T, Weiss J, et al: Screening mammography intervals among postmenopausal hormone therapy users and nonusers. Cancer Causes Control 21:147-152, 2010
29. Cleator SJ, Ahamed E, Coombes RC, et al: A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 9:S6-S17, 2009 (suppl 1)
30. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer - Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350:1047-1059, 1997
31. Ereman RR, Prebil LA, Mockus M, et al: Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. BMC Public Health 10:228, 2010
32. Séradour B, Allemand H, Weill A, et al: Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 96:E1-E6, 2009
33. Stefanick ML, Anderson GL, Margolis KL, et al: Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647-1657, 2006